Experiences with

Ozanimod

[i]Clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients in all age groups over 7 to 8 years of continuous treatment with (Zeposia).

My MSAA Community members, Please see info from MSAA on the recently-announced news of the commercial launch and availability of Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis - learn more in the Latest News link below: https://mymsaa.org/news/launch-of-zeposia-announced

Please see below for a link to MSAA's latest news update about the FDA approval of Zeposia® (ozanimod) for relapsing forms of MS: https://mymsaa.org/news/fda-approves-zeposia-for-relapsing-ms Thank you, Emily

forms of multiple sclerosis will have another oral treatment option with meaningful efficacy to help address the disease’s hallmark relapses and brain lesions,” said Samit Hirawat, MD, the company’s chief medical officer. https://multiplesclerosisnewstoday.com/news-posts/2020/03/26/fda-approves-zeposia-ozanimod-oral-rrms-active-spms-cis-therapy